Hormone Therapy

Question 1

Prednisone (Meticorten) Class

Answer 1

Glucocorticoids

Question 2

Prednisone (Meticorten) Mechanism

Answer 2

Inhibit mitosis in lymphocytes

Question 3

Prednisone (Meticorten) Therapeutics

Answer 3

ALL; combination for Hodgkin’s, non-Hodkin’s, multiple myeloma, and CLL

Question 4

Dexamethasone (Decadron) Class

Answer 4

Glucocorticoids

Question 5

Dexamethasone (Decadron) Mechanism

Answer 5

Inhibit mitosis in lymphocytes

Question 6

Dexamethasone (Decadron) Therapeutics

Answer 6

Reduces edema in brain and spinal cord tumors with radiation therapy

Question 7

Tamoxifen (Soltamox) Class

Answer 7

Selective estrogen-receptor modulators(SERMs)

Question 8

Tamoxifen (Soltamox) Mechanism

Answer 8

Competes with estradiol for binding to estrogen receptor

Question 9

Tamoxifen (Soltamox) Therapeutics

Answer 9

ER-positive breast cancer, or as adjuvant therapy following primary breast tumor excision; prevention of breast cancer in high-risk patients

Question 10

Tamoxifen (Soltamox) Important side effects

Answer 10

Hot flushes, hair loss; increased risk of endometrial cancer;increased risk of thromboembolic events

Question 11

Tamoxifen (Soltamox) Other side effects

Answer 11

Nausea and vomiting

Question 12

Fulvestrant (Faslodex) Class

Answer 12

Selective estrogen-receptor downregulators(SERDs)

Question 13

Fulvestrant (Faslodex) Mechanism

Answer 13

Binds with much higher affinity (>100-fold)to estrogen receptor than tamoxifen,inhibiting dimerization, increasing degradation, and reducing overall ER levels

Question 14

Fulvestrant (Faslodex) Therapeutics

Answer 14

Posmenopausal women with ER positive metastatic breast cancer

Question 15

Aminoglutethamide (Cytadren) Class

Answer 15

Aromatase inhibitors

Question 16

Aminoglutethamide (Cytadren) Mechanism

Answer 16

Inhibits function of aromatase

Question 17

Aminoglutethamide (Cytadren) Therapeutics

Answer 17

Relatively weak, used against breastcancer

Question 18

Anastrozole (Arimidex) Class

Answer 18

Aromatase inhibitors

Question 19

Anastrozole (Arimidex) Mechanism

Answer 19

Inhibits function of aromatase

Question 20

Anastrozole (Arimidex) Therapeutics

Answer 20

First-line for ER-positive breast cancer in postmenopausal women

Question 21

Letrozole (Femara) class

Answer 21

Aromatase inhibitors

Question 22

Letrozole (Femara) Mechanism

Answer 22

Inhibits function of aromatase

Question 23

Letrozole (Femara) Therapeutics

Answer 23

ER-positive breast cancer in postmenopausal women

Question 24

Exemestane (Aromasin) class

Answer 24

Aromatase inhibitors

Question 25

Exemestane (Aromasin) Mechanism

Answer 25

Steroidal inhibitor of aromatase

Question 26

Exemestane (Aromasin) Therapeutics

Answer 26

ER-positive breast cancer in postmenopausal women

Question 27

Leuprolide (Lupron) class

Answer 27

GnRH analogs

Question 28

Leuprolide (Lupron) Mechanism

Answer 28

Binds GnRH receptor; inhibits release of FSH & LH

Question 29

Leuprolide (Lupron) Therapeutics

Answer 29

Androgen ablation therapy, along with AR blockers

Question 30

Goserelin (Zoladex) Class

Answer 30

GnRH analogs

Question 31

Goserelin (Zoladex) Mechanism

Answer 31

Binds GnRH receptor; inhibits release of FSH & LH

Question 32

Goserelin (Zoladex) Therapeutics

Answer 32

Androgen ablation therapy, along with AR blockers

Question 33

Flutamide (Eulexin) Class

Answer 33

Nonsteroidal androgen-receptor blockers

Question 34

Flutamide (Eulexin) Mechanism

Answer 34

Competes with androgen for AR binding

Question 35

Flutamide (Eulexin) Therapeutics

Answer 35

Androgen ablation therapy, along with GnRH analogs

Question 36

Bicalutamide (Casodex) Class

Answer 36

Nonsteroidal androgen-receptor blockers

Question 37

Bicalutamide (Casodex) Mechanism

Answer 37

Competes with androgen for AR binding

Question 38

Bicalutamide (Casodex) Therapeutics

Answer 38

Androgen ablation therapy, along with GnRH analogs